Haematological Diagnosis

Coordinator
Nomdedéu Guinot, Josep Francesc FGS
jnomdedeu@santpau.cat

Members
Blanco, Maria Laura FGS
Bussaglia Petrillo, Elena Mart FGS
Carricondo Morcillo, Maite FGS
Espadaler Pare, Montserrat FGS
Estivill Riezu, María Camino FGS
Fernández Rosales, María Nieves FGS
Fuentes Hernández, Francisca FGS
Hernández Campos, Carmen FGS
Martínez Sánchez, Elisabeth FGS
Martínez Valverde, Clara Maria FGS
Ortin Quílez, Rosa FGS
Pratcorona Canela, Marta FGS
Remacha Sevilla, Ángel Francisco FGS
Rubio Olmos, Miguel Ángel IR
Sarda Vidal, Maria Pilar FGS
Serra Ferrer, Marta FGS
Úbeda Rodenas, Jose FGS

Main Lines of Research

- Hematologic malignacies: diagnostics (morphology, cytogenetics, flow cytometry, molecular diagnostics).
- Next generation sequencing, genomic (microarrays) and proteomic platforms for diagnosis.
- Patient's derived xenografts.
- Noncancerous haemopathologies
- Diagnosis and characterization of thrombocytopenias, thrombocytopathies and other platelet pathologies, especially complex pathologies (of genetic, mixed or unknown origin) and including unusual presentations of common diseases.
- In the framework of the GAIT-2 (genetic analysis of idiopathic thrombophilia, phase 2) project, to seek new phenotypes that favour the development of thrombosis, specifically related to the structure and function of platelets and other blood cells.

Challenges

- Consolidate characterization of haematological tumours and complex, rare and genetic noncancerous haematopathologies.
- Sampling management: isolation of neoplastic and non-neoplastic cells.
- Include the results of mass-analysis genomic and proteomic platforms in diagnostic algorithms and establish prognostic factors for haematological disorders, preferably complex or genetic neoplasms and noncancerous pathologies.
- Set up animal models in hematologic malignancies.
- Consolidate cooperation with the GAIT-2 project, especially regarding platelet and other blood cell participation in thrombosis generation.
- Promote interaction and stable links with internal groups (clinical hematology, pathology, gastrointestinal, hemostasis and thrombosis, complex disease genomics areas) and with other groups in Spain and abroad, especially those with complementary technologies.

Collaborations

Collaborations with other IIB Sant Pau Group

- Dr. Matilde Parreño:
  - Josep Francesc Nomdedéu Guinot, Matilde Parreño. Instituto de Salud Carlos III. PI/00940. Duration: 2017-2019. 80,465 €.
  - Support grants to the Research Groups of Catalonia. Grup de Diagnòstic Hematològic. AGAUR 2017. 2017-SGR-383. Duration: 2017-2019.
- Oncology/Haematology and Transplantation (PI: Jordi Sierra).
- Molecular Bases of Disease (PI: Pablo Fuentes).
- Dr. Ramon Mangues/Isolda Casanova.

External Collaborations

- Dr. G. Saglio. Torino University.
- Dr. G. Gaidano. Novara University.
- Dr. Anna Bigas, IMIM (Hospital del Mar).
- Dr. Luciano di Croce. CRG. Barcelona.
- Dr. Pablo Menéndez. Josep Carreras Foundation (Hospital Clínic).
- Dr. Alberto Villanueva. IDIBELL-Bellvitge Biomedical Research Institute.
- Dr. G. Vassiliou. Sanger Center. Cambridge. UK

Active Grants

- Josep Francesc Nomdedéu Guinot. Diagnostic Hematologic. 2014 SGR 383. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 30,000.00 €.
- Josep Francesc Nomdedéu Guinot. Heterogeneidad clonal en leucemia mieloide aguda: caracterización inmunofenotípica, genotípica y mediante generación de xenografts. PI16/00940. Instituto de Salud Carlos III. Duration: 2017-2019. 66,500.00 €

Note: Total amount granted to PI. It does not include indirect costs.

Scientific Production

***TIF: 18.71 **MIF: 3.742**

Bosch R., Mora A., Vicente E.P., Ferrer G., Jansa S., Damle R., Gorlatov S., Rai K., Montserrat E., Nomdedeu J., Pratcorona M., Blanco L., Saavedra S., Garrido A., Esquirol A., Garcia I., Granell M., Martino R., Delgado J., Sierra J., Chiorazzi N., Moreno C., FcγRIIb expression in early stage chronic lymphocytic leukemia (2017) LEUKEMIA LYMPHOMA, 58 (11), 2642-2648.
IF: 2.644

Diaz de la Guardia R., Lopez-Millan B., Lavoie J.R., Bueno C., Castano J., Gomez-Casares M., Vives S., Palomo L., Juan M., Delgado J., Blanco M.L., Nomdedeu J., Chaparro A., Fuster J.L., Anguita E., Rosu-Myles M., Menendez P., Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes (2017) STEM CELL REP, 8 (6), 1573-1586.
IF: 6.537

Gomez Ramirez S., Remacha Sevilla A.F., Munoz Gomez M., Anaemia in the elderly Anemia del anciano (2017) MED CLIN-BARCELONA, 149 (11), 496-503.
IF: 1.168

Nomdedeu J.F., Puigdecanet E., Bussaglia E., Hernandez J.J., Carricondo M., Estivill C., Marti-Tutusaus J.M., Tormo M., Zamora L., Serrano E., Perea G., de Llano M.P.Q., Garcia A., Sanchez-Ortega I., Ribera J.M., Nonell L., Aventin A., Sole F., Brunet M.S., Sierra J., Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach (2017) HEMATOL ONCOL, 35 (4), 778-788.
IF: 3.193

Pallares V., Hoyos M., Chillon M.C., Barragan E., Conde M.I.P., Llop M., Cespedes M.V., Nomdedeu J.F., Brunet S., Sanz M.A., Gonzalez-Diaz M., Sierra J., Casanova I., Mangues R., NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients (2017) ONCOTARGET, 8 (44), 76003-76014.
IF: 5.1680

*Total Impact Factor **Mean Impact Factor